AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
Weng W, Meng T, Pu J, Ma L, Shen Y, Wang Z, Pan R, Wang M, Chen C, Wang L, Zhang J, Zhou B, Shao S, Qian Y, Liu S, Hu W, Meng X.
Weng W, et al. Among authors: hu w.
Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. doi: 10.1158/1535-7163.MCT-23-0198.
Mol Cancer Ther. 2023.
PMID: 37302522
Free PMC article.